You are reading 1 of 2 free-access articles allowed for 30 days
The CRDI is the new name for the Molecular Medicine Ireland (MMI), a not for profit partnership established in 2002 by NUI Galway, Royal College of Surgeons in Ireland, Trinity College Dublin, University College Cork and University College Dublin.
According to the CRDI, Ireland has significant potential to increase its clinical research activities.
Since it was first established in 2002, it has provided training, including structured PhD programmes and Good Clinical Practice (GCP) courses, to over 4,600 Irish researchers and it has jointly facilitated almost 200 clinical research studies.
“Currently we estimate that less than 2 percent of Irish adult patients are offered the opportunity to participate in clinical research as part of their medical treatment; the international target is circa 10 percent,” said Dr Pat O’Mahony, Chief Executive of CRDI,
“So there is a significant opportunity to increase clinical research in Ireland that would also enable Irish patients to potentially access new and emerging therapies.”
Dr O’Mahony said that in health systems where clinical research infrastructure and delivery are better developed, there are significant benefits for patients in terms of better outcomes.
“It is undisputed that a strong clinical research infrastructure offers a host of benefits to the wider healthcare system including improved outcomes for patients, better use of scarce resources, and improved clinical staff recruitment and retention,” said Dr O’Mahony.